ArticleAntimicrobial agents and chemotherapy2012
Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 141 citations in OpenAlex.
- Modeling Phage-Antibiotic Synergy, Innate Immunity, and Phage Resistance in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- The Therapeutic Potential of Phages in Multi-Drug Resistance Infections and Future Directions.Viruses · 2026Review
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Phage Therapy at the Crossroads Between Clinical Promise and Regulatory Challenge.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Management of Diabetic Foot Infections Using Phage Therapy.Infection and drug resistance · 2026Review
- Targeting multidrug-resistant Escherichia coli by two isolated bacteriophages from hospital wastewater.Folia microbiologica · 2025Article
- PSK1, a bacteriophage with antibacterial activity against extended-spectrum-beta-lactamase-producing Escherichia coli sequence type 131 with serotype O25:H4.Archives of virology · 2025Article
- The virulent bacteriophage Henu8 as an antimicrobial synergist againstMicrobiology spectrum · 2025Article
- Phage-induced protection against lethal bacterial reinfection.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Isolation and characterization of new lytic bacteriophage PSA-KC1 against Pseudomonas aeruginosa isolates from cystic fibrosis patients.Scientific reports · 2025Article
- Variable fitness effects of bacteriophage resistance mutations inJournal of virology · 2024Article
- Review
- Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections.Clinical microbiology reviews · 2024Review
- Phages produce persisters.Microbial biotechnology · 2024Article
- Mini review advantages and limitations of lytic phages compared with chemical antibiotics to combat bacterial infections.Heliyon · 2024Review
- CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Exploiting lung adaptation and phage steering to clear pan-resistant Pseudomonas aeruginosa infections in vivo.Nature communications · 2024Article
- Efficacy and Experience of Bacteriophages in Biofilm-Related Infections.Antibiotics (Basel, Switzerland) · 2024Review
- Postbiotic as Novel Alternative Agent or Adjuvant for the Common Antibiotic Utilized in the Food Industry.Current pharmaceutical biotechnology · 2024Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated phage therapy in experimental infections due to S242, a fatal neonatal meningitis Escherichia coli strain belonging to the worldwide-distributed O25b:H4-ST131 clone that produces extended-spectrum beta-lactamase CTX-M-15. A lytic phage, EC200(PP), active against S242, was isolated from environmental water. After determining in vitro and ex vivo stabilities and pharmacokinetic properties of EC200(PP) in rat pups, we assessed the therapeutic efficacy of a single dose of 10(8) PFU using models of sepsis and meningitis in which fatality was 100%. EC200(PP) was partially neutralized by human serum. In contrast to the high concentration of phage in the spleen and the kidney, low titers in urine and the central nervous system were observed. Nevertheless, in the sepsis model, EC200(PP) administered 7 h or 24 h postinfection resulted in 100% and 50% pup survival, respectively. In the meningitis model, EC200(PP) administered 1 h or 7 h postinfection rescued 100% of the animals. The most delayed treatments were associated with the selection of phage-resistant S242 mutants. However, a representative mutant was highly sensitive to killing serum activity and avirulent in an animal model. EC200(PP) is a potential therapeutic agent for sepsis and meningitis caused by the widespread E. coli O25:H4-ST131 multidrug-resistant clone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.